This means the medicines should not be provided on the NHS as they are not good value for money. Last month the appraisal committee met to consider new information submitted as part of its additional ...

With only 1 in 5 donated lungs currently considered suitable for use, the introduction of the XVIVO Perfusion System for a 4-year period while evidence is generated, could benefit hundreds of NHS ...

Thousands of people in England with a type of chronic heart failure are eligible for a new treatment option following our final draft guidance that recommends finerenone for adults with chronic heart ...

Gavin Redhead, a patient advocate, tells us how heart failure healthtech recommended by NICE helped transform his life.

When a decision is made to prescribe antibiotics, the shortest course that is likely to be effective should be prescribed to reduce the risk of antimicrobial resistance and adverse effects. Short ...

NICE is unable to make a recommendation on lutetium-177 vipivotide tetraxetan (Pluvicto) for treating prostate-specific membrane antigen (PSMA)-positive hormone-relapsed metastatic prostate cancer in ...

Independent committees develop our recommendations. NICE committees are made up of people like you. They include experts in health and social care, people who use health and care services and carers.

There are different ways to get involved in NICE’s work and help us to improve NHS and care services for other people – either those who are like you, or those communities you represent as part of a ...

Evidence-based recommendations on dostarlimab (Jemperli) with platinum-containing chemotherapy for primary advanced or recurrent endometrial cancer with microsatellite stability or mismatch repair ...

Decisions about updating our guidance are made by NICE’s prioritisation board. For more information on the principles and process, see NICE-wide topic prioritisation: the manual. For information about ...

NICE is unable to make a recommendation on sirolimus (Hyftor) for treating facial angiofibroma caused by tuberous sclerosis complex in people 6 years and over. This is because Plusultra pharma did not ...

This guideline covers diagnosing and managing multiple sclerosis in people aged 18 and over. It aims to improve the quality of life for people with multiple sclerosis by promoting prompt and effective ...